Teleflex (TFX) said Wednesday that the US Food and Drug Administration gave 501(k) clearance for expanded use of the QuikClot Control+ hemostatic device to include all grades of internal and external bleeding.
The expanded clearance covers procedures in general surgery, gynecologic surgery, orthopedic surgery and other areas, the company added.
The expanded use will add more than $150 million to the company's serviceable addressable market in the US, according to Teleflex.
Shares of the company were down 3% in recent trading.
Price: 134.33, Change: -3.89, Percent Change: -2.81
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。